Objective Neurocognitive Assessment of Young Children With Sickle Cell Disease by Eye-Tracking (ONSET)
Visão geral do estudo
Status
Descrição detalhada
Objective: The main aim is to study early neurocognitive functioning and development in very young children with SCD. The secondary aims are to 1) (i) identify demographic, psychosocial and clinical determinants and (ii) identify biomarkers associated with early neurocognitive deficits in young children with SCD. 2) Analyze the association between early neurocognitive functioning and adaptive daily life functioning.
Study design: Prospective observational study with an accelerated longitudinal design. The accelerated longitudinal design allows for the inclusion of children from a broad age range (6 - 24 months). During the total study period of 30 months, children can enroll in the study at the ages of 6, 12, 18 and 24 months. After enrollment, children will visit every 6 months until they reach the age of 24 months. This design spans the age range of interest in a shorter period of time and a smaller load on participants as compared to a conventional longitudinal design.
Methods: Eye-tracking measurements will take place at every study visit. Demographic, psychosocial and clinical characteristics of the SCD group will be collected using prospective and structured clinical registration as part of regular clinical care. Demographic, psychosocial and clinical information of the control group will be collected using a parent questionnaire administered during the first and last study visit. Blood samples of children with SCD will be taken as part of regular blood checks at the age of 12 and/or 24 months (depending on the age of enrollment in the study). The Child Behavior Checklist, TNO AZL Preschool Children Quality of Life and the Bayley Scale of Infant and Child Development will be administered to all children at the age of 24 months.
Main study parameters/endpoints: Neurocognitive functioning, as measured using eye-tracking.
Secondary study parameters/ endpoints: The following determinants will be measured: Demographic, psychosocial and clinical characteristics, as measured as part of regular clinical care (SCD group) or via parent questionnaire (control group) and Biomarkers, as measured in blood (SCD group). Adaptive daily life functioning, as measured by quality of life, behavioural and emotional functioning questionnaire, and general (cognitive) development assessment.
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
-
Amsterdam, Holanda, 1105AZ
- Amsterdam UMC
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Age 6 - 24 months old
- Inhabitant of the Netherlands
- Written informed consent from parent/caretaker.
Exclusion Criteria:
- Refused informed consent from parents/care-taker
- Diagnosis of visual impairment (which cannot be corrected by glasses)
- Diagnosis of a (co-morbid) congenital developmental condition
- Any neurological condition, unrelated to SCD, that could affect the central nervous system, such as brain trauma, epilepsy and meningitis/encephalitis.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Patient group
Infants between 6 and 24 months of age diagnosed with sickle cell disease
|
Eye-tracking is an objective, non-invasive method and particularly suited to assess neurodevelopmental outcome in infants.
proteomics analyses methylation analyses
The strengths and difficulties questionnaire is a conventional instrument used to measure the presence of psychosocial problems, the child's strengths and the influence of psychosocial problems on daily functioning.
The TNO-AZL Preschool Children Quality of Life is a questionnaire that measures the health-related quality of life of children over the last three months
The Bayley Scale of Infant Development is a conventional instrument used to measure developmental outcome in infants
|
|
Healthy subject group
Infants between 6 and 24 months of age without sickle cell disease
|
Eye-tracking is an objective, non-invasive method and particularly suited to assess neurodevelopmental outcome in infants.
The strengths and difficulties questionnaire is a conventional instrument used to measure the presence of psychosocial problems, the child's strengths and the influence of psychosocial problems on daily functioning.
The TNO-AZL Preschool Children Quality of Life is a questionnaire that measures the health-related quality of life of children over the last three months
The Bayley Scale of Infant Development is a conventional instrument used to measure developmental outcome in infants
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Processing speed in the gap condition (Gap/Overlap task)
Prazo: T1 (age 6 months), T2 (age 12 months), T3 (age 18 months), T4 (age 24 months)
|
The speed of responding to a novel peripheral stimulus when the central stimulus disappears before the peripheral target appears.
Measured as reaction time (RT) via eye-tracking in infants with sickle cell disease (SCD).
Unit of Measure: Milliseconds (ms)
|
T1 (age 6 months), T2 (age 12 months), T3 (age 18 months), T4 (age 24 months)
|
|
Processing accuracy in the gap condition (Gap/Overlap task)
Prazo: T1 (age 6 months), T2 (age 12 months), T3 (age 18 months), T4 (age 24 months)
|
The precision of responding to a novel peripheral stimulus when the central stimulus disappears before the peripheral target appears. Measured as a binomial outcome (accurate/inaccurate) per trial via eye-tracking in infants with SCD. Unit of Measure: Proportion of accurate trials |
T1 (age 6 months), T2 (age 12 months), T3 (age 18 months), T4 (age 24 months)
|
|
Orienting attention speed in the overlap condition (Gap/Overlap task)
Prazo: T1 (age 6 months), T2 (age 12 months), T3 (age 18 months), T4 (age 24 months)
|
The speed of orienting attention away from a central stimulus toward a peripheral target when the central stimulus remains on screen. Measured as RT in the overlap condition expressed as percentage change relative to mean RT in the gap condition, via eye-tracking in infants with SCD. Unit of Measure: Percentage (%) |
T1 (age 6 months), T2 (age 12 months), T3 (age 18 months), T4 (age 24 months)
|
|
Orienting attention accuracy in the overlap condition (Gap/Overlap task)
Prazo: T1 (age 6 months), T2 (age 12 months), T3 (age 18 months), T4 (age 24 months)
|
The precision of orienting attention toward a peripheral target when the central stimulus remains on screen. Measured as a binomial outcome (accurate/inaccurate) per trial via eye-tracking in infants with SCD. Unit of Measure: Proportion of accurate trials |
T1 (age 6 months), T2 (age 12 months), T3 (age 18 months), T4 (age 24 months)
|
|
Alerting attention without external cues (Gap/Overlap task)
Prazo: T1 (age 6 months), T2 (age 12 months), T3 (age 18 months), T4 (age 24 months)
|
The ability to maintain focus on the task without external attention-grabbing cues. Measured as a binomial outcome per trial (completed without attention grabber: yes/no) via eye-tracking in infants with SCD. Unit of Measure: Proportion of trials completed without attention grabber |
T1 (age 6 months), T2 (age 12 months), T3 (age 18 months), T4 (age 24 months)
|
|
Sustained attention across trials (Gap/Overlap task)
Prazo: T1 (age 6 months), T2 (age 12 months), T3 (age 18 months), T4 (age 24 months)
|
The ability to attend to the task over a longer period. Measured as the number of trials completed expressed as a percentage of the total possible trials, via eye-tracking in infants with SCD. Unit of Measure: Percentage (%) |
T1 (age 6 months), T2 (age 12 months), T3 (age 18 months), T4 (age 24 months)
|
|
Fixation duration during free viewing (Freeview task)
Prazo: T1 (age 6 months), T2 (age 12 months), T3 (age 18 months), T4 (age 24 months)
|
The amount of time the eyes remain stably focused on a specific location, defined as periods of stable gaze between successive saccades. Measured as mean fixation duration via eye-tracking in infants with SCD. Unit of Measure: Milliseconds (ms) |
T1 (age 6 months), T2 (age 12 months), T3 (age 18 months), T4 (age 24 months)
|
|
Habituation (Habituation task)
Prazo: T1 (age 6 months), T2 (age 12 months), T3 (age 18 months), T4 (age 24 months)
|
The process of becoming accustomed to a repeatedly presented stimulus. Measured as the number of trials required to reach the pre-defined habituation criterion via eye-tracking in infants with SCD. Unit of Measure: Number of trials |
T1 (age 6 months), T2 (age 12 months), T3 (age 18 months), T4 (age 24 months)
|
|
Recognition (Habituation task)
Prazo: T1 (age 6 months), T2 (age 12 months), T3 (age 18 months), T4 (age 24 months)
|
The ability to distinguish a previously presented stimulus from a novel one. Measured as the absolute difference in looking time toward the habituation stimulus versus the novel stimulus, via eye-tracking in infants with SCD. Unit of Measure: Percentage (%) |
T1 (age 6 months), T2 (age 12 months), T3 (age 18 months), T4 (age 24 months)
|
|
Novelty preference (Habituation task)
Prazo: T1 (age 6 months), T2 (age 12 months), T3 (age 18 months), T4 (age 24 months)
|
The tendency to inspect a novel stimulus relative to a previously presented one. Measured as looking time toward the novel stimulus as a percentage of total looking time, via eye-tracking in infants with SCD. Unit of Measure: Percentage (%) |
T1 (age 6 months), T2 (age 12 months), T3 (age 18 months), T4 (age 24 months)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Demographic and perinatal characteristics assessed via parent-reported questionnaire
Prazo: At study visit of 6, 12 18 or 24 months of age, depending on the enrollment age. The first visit in the study
|
Demographic and perinatal information collected via a structured parent/caretaker questionnaire, including child age, sex, ethnicity, country of origin, parental education level (as proxy for socioeconomic status), and perinatal information (e.g. breastfeeding, birth characteristics). Clinical characteristics (e.g. SCD genotype, disease severity, treatment) are extracted from electronic health records. Unit of Measure: Categorical and continuous variables (reported descriptively) |
At study visit of 6, 12 18 or 24 months of age, depending on the enrollment age. The first visit in the study
|
|
Behavioral and emotional functioning assessed using the Strengths and Difficulties Questionnaire (SDQ)
Prazo: study visit at 24 months of age
|
Parent-reported behavioral and emotional functioning measured using the SDQ, a validated screening instrument. The SDQ assesses five domains: emotional symptoms, conduct problems, hyperactivity/inattention, peer relationship problems, and prosocial behavior. Scores are reported per subscale and as a total difficulties score. Unit of Measure: Scale score (0-40 total difficulties score) |
study visit at 24 months of age
|
|
Development assessed using the Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III)
Prazo: study visit at 24 months of age
|
Standardized assessment of development administered by a trained examiner at age 24 months using the BSID-III (Cognitive and Motor Scale).
Scores are reported as scaled scores with a normative mean of 10 (SD=3).
Unit of Measure: Scaled score
|
study visit at 24 months of age
|
|
Plasma proteomic biomarker profile assessed via blood sample in children with SCD
Prazo: study visit at 12 months of age and study visit at 24 months of age
|
A blood sample is collected from children with SCD to identify plasma proteomic biomarkers related to disease severity and neurological functioning. Samples are analyzed using unbiased proteomics analyses to characterize protein expression profiles. Unit of Measure: Protein expression levels (reported as relative abundance) |
study visit at 12 months of age and study visit at 24 months of age
|
Colaboradores e Investigadores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- NL82004.018.22
- 2022.0539 (Outro identificador: Amsterdam UMC)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .